Ki67 is present during all active phases of the cell cycle (G1, S, G2, and M) but absent in resting cells (G0), making it a key marker for assessing tumor cell proliferation
These values were derived from ROC curve analysis in a single-center study of 89 women and have not yet been externally validated or standardized across centers
Verify current plan-specific details on the Blue Shield of CA drug-lookup tool

expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations

They must have taken the drug for at least 90 continuous days and stayed off other GLP-1 agonists for at least a year
Roszczenko P, Radomska KA, Wywial E, Collet J-F, Jagusztyn-Krynicka EK (2012) A novel insight into the oxidoreductase activity of Helicobacter pylori HP0231 protein